ARTICLE | Company News
Isis, Merck deal
March 26, 2001 8:00 AM UTC
The companies extended for an additional year their deal to develop therapeutics for hepatitis C virus (HCV) infection (see BioCentury, June 15, 1998). ISIP will receive research support and milestone...